The FDA has accepted for review the resubmitted NDA for elamipretide in the treatment of Barth syndrome, a rare mitochondrial disease.

SCA slowdown, with FDA review set for Q4 2025 and no advisory meeting required. Find out why BHVN stock is a strong buy.

Breakthrough Therapy designation complements Rusfertide's Orphan Drug and Fast Track designations, which together confer ...

The LJP (RV) remains the toughest nut to crack. Despite winning only one seat in 2020, its aggressive strategy hurt JDU in 27 ...

Rajamahendravaram: Congress Working Committee (CWC) member and former PCC president Gidugu Rudra Raju on Sunday alleged that ...

Amit Shah endorsed the NDA's decision to name Maharashtra Governor CP Radhakrishnan as its Vice Presidential candidate, ...

Union Home Minister Amit Shah endorsed the NDA's decision to name Maharashtra Governor CP Radhakrishnan as its Vice ...

Alleged NDA ties Ripple, JPMorgan, & BlackRock to XRPL identity protocol. Raises digital ID, tokenized assets, & settlement rails questions.

At the end of last season, Notre Dame Academy’s (NDA) football team achieved a monumental milestone — its third state ...

Jessica Simpson, newly single at 45, is reportedly seeking casual hookups with younger men while keeping the door open for ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the most promising future stocks according to Wall Street analysts.

On a very good Friday for the stock market, Biohaven 's (NYSE: BHVN) performance was exceptional. The clinical-stage biotech ...